Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma.
Tanabe N, Saeki I, Aibe Y, Matsuda T, Hanazono T, Nishi M, Hidaka I, Kuwashiro S, Shiratsuki S, Matsuura K, Egusa M, Nishiyama N, Fujioka T, Kawamoto D, Sasaki R, Nishimura T, Oono T, Hisanaga T, Matsumoto T, Ishikawa T, Yamasaki T, Takami T.
Tanabe N, et al. Among authors: kawamoto d.
Cancers (Basel). 2023 May 26;15(11):2927. doi: 10.3390/cancers15112927.
Cancers (Basel). 2023.
PMID: 37296889
Free PMC article.